TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39483049

Group type: EXPERIMENTAL
Intervention: Non-selective closed kinetic chain exercises (NSKCE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Selective closed kinetic chain exercises (SCKCE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Control group (healthy controls)
Number of subjects: 80
Study: 39483442

Group type: EXPERIMENTAL
Intervention: Group Metacognitive Therapy (MCT) added to usual CR
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Cardiac Rehabilitation (CR)
Number of subjects: 0
Study: 39483517

Group type: EXPERIMENTAL
Intervention: Deferred local treatment of the primary tumour (experimental arm) consisting of (partial) cytoreductive nephrectomy, any form of ablative local therapy, or magnetic resonance imaging guided ablative stereotactic radiotherapy, performed within 6 months and 1.5 years after the start of systemic treatment.
Number of subjects: 700

Group type: COMPARATOR
Intervention: Standard of care (SOC) (control arm).
Number of subjects: 700
Study: 39483518

Group type: EXPERIMENTAL
Intervention: Multiomics and immunohistopathological analyses on biosamples (blood, urine, and BC tissue) collected from patients at diagnosis.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Multiomics analyses to identify multibiomarker panels for better stratification of NMIBC.
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Analysis of patient subgroup response to bacillus Calmette-Guérin treatment.
Number of subjects: 300
Study: 39483619

Group type: EXPERIMENTAL
Intervention: AFQ056 (mavoglurant)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39483877

Group type: EXPERIMENTAL
Intervention: TARANG intervention
Number of subjects: 42
Study: 39483896

Group type: EXPERIMENTAL
Intervention: Targeted implementation support (training, championship, practice facilitation, audit and feedback)
Number of subjects: 20
Study: 39483915

Group type: EXPERIMENTAL
Intervention: AI-driven OUD screener embedded in the electronic health record (EHR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 39484118

Group type: EXPERIMENTAL
Intervention: Antidepressant use at baseline
Number of subjects: 784

Group type: COMPARATOR
Intervention: Mild depression
Number of subjects: 784
Study: 39484131

Group type: EXPERIMENTAL
Intervention: SII Q1: <1707.31 (×10)
Number of subjects: 3808

Group type: COMPARATOR
Intervention: SII Q2: ≥1707.31 (×10)
Number of subjects: 3808
Study: 39484239

Group type: EXPERIMENTAL
Intervention: Nightmode decoder for brain-computer interface (BCI)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daytime decoders
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nightmode decoder
Number of subjects: 0
Study: 39484240

Group type: EXPERIMENTAL
Intervention: aTIV (adjuvanted trivalent inactivated flu vaccine)
Number of subjects: 387

Group type: COMPARATOR
Intervention: HD-IIV3 (high-dose flu vaccine)
Number of subjects: 387
Study: 39484244

Group type: EXPERIMENTAL
Intervention: WSH or nutrition interventions
Number of subjects: 1409

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1409
Study: 39484284

Group type: EXPERIMENTAL
Intervention: CH505TF + GLA-SE
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 39485113

Group type: EXPERIMENTAL
Intervention: Hybrid nuclear and fluoroscopy C-arm scanner
Number of subjects: 12
Study: 39485256

Group type: EXPERIMENTAL
Intervention: Personalized neoantigen-encoding mRNA vaccines
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Individualized vaccines plus pembrolizumab
Number of subjects: 16
Study: 39485259

Group type: EXPERIMENTAL
Intervention: Oral administration of the intervention (specific intervention not mentioned)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 0
Study: 39485352

Group type: EXPERIMENTAL
Intervention: Yoga now (virtual yoga classes)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Yoga later (wait-list control)
Number of subjects: 140
Study: 39485351

Group type: EXPERIMENTAL
Intervention: Liberal RBC transfusion strategy (Hb <10 g/dL)
Number of subjects: 3144

Group type: COMPARATOR
Intervention: Restrictive RBC transfusion strategy (Hb <7-8 g/dL)
Number of subjects: 3144

Group type: EXPERIMENTAL
Intervention: Acute anemia
Number of subjects: 3144

Group type: EXPERIMENTAL
Intervention: Chronic anemia
Number of subjects: 3144
Study: 39485534

Group type: EXPERIMENTAL
Intervention: Voxel-wise compartmental analysis of dynamic imaging
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Delaying the starting point of the compartmental analysis
Number of subjects: 11
Study: 39485585

Group type: EXPERIMENTAL
Intervention: HRV-BfB training (live format)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: HRV-BfB training (digital format)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 73
Study: 39485702

Group type: EXPERIMENTAL
Intervention: Urine pH-Ammonium Acid/Base Score
Number of subjects: 0
Study: 39485760

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri ATCC PTA 6475 (single strain)
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri DSM 17938 (dual strain)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study: 39485833

Group type: EXPERIMENTAL
Intervention: Micra AV leadless pacemaker
Number of subjects: 116110

Group type: COMPARATOR
Intervention: DC-TV pacemaker
Number of subjects: 116110
Study: 39485887

Group type: EXPERIMENTAL
Intervention: Superior mesenteric artery approach
Number of subjects: 101

Group type: COMPARATOR
Intervention: No-touch approach
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Intraoperative cluster mobilization
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Vein resection
Number of subjects: 101
Study: 39486004

Group type: EXPERIMENTAL
Intervention: 3D printed permanent ceramic-filled resin (PCR) restorations
Number of subjects: 30
Study: 39486022

Group type: EXPERIMENTAL
Intervention: Partner-CHESS app
Number of subjects: 33

Group type: COMPARATOR
Intervention: A-CHESS app
Number of subjects: 33
Study: 39486046

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan 270 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan 360 mg/day
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Pegcetacoplan (both dosages)
Number of subjects: 24
Study: 39486089

Group type: EXPERIMENTAL
Intervention: 100 mg ibuzatrelvir
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 300 mg ibuzatrelvir
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: 600 mg ibuzatrelvir
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 240
Study: 39486163

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI every 2 weeks after failure of a prior oxaliplatin-based regimen
Number of subjects: 137

Group type: EXPERIMENTAL
Intervention: Aflibercept plus FOLFIRI
Number of subjects: 137
Study: 39486165

Group type: EXPERIMENTAL
Intervention: Talazoparib plus enzalutamide
Number of subjects: 596
Study: 39486209

Group type: EXPERIMENTAL
Intervention: Pain neuroscience education program (PNE) - 10 sessions over 5 weeks, each lasting 40-45 minutes.
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Standard treatment supplemented with PNE
Number of subjects: 62

Group type: COMPARATOR
Intervention: Standard pharmacological treatment
Number of subjects: 62
Study: 39486411

Group type: EXPERIMENTAL
Intervention: Neoadjuvant TLR9 agonist vidutolimod combined with anti-PD-1 nivolumab
Number of subjects: 31
Study: 39486424

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab
Number of subjects: 216

Group type: COMPARATOR
Intervention: Chemotherapy (carboplatin plus pemetrexed)
Number of subjects: 216
Study: 39486432

Group type: EXPERIMENTAL
Intervention: Valemetostat 150 mg per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valemetostat 200 mg per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valemetostat 250 mg per day
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Valemetostat 300 mg per day
Number of subjects: 90
Study: 39486433

Group type: EXPERIMENTAL
Intervention: Valemetostat at 200 mg per day in continuous 28-day cycles until disease progression or unacceptable toxicity
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Valemetostat
Number of subjects: 155
Study: 39486439

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri DSM 17938 supplementation for six weeks
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Limosilactobacillus reuteri DSM 17938 supplementation
Number of subjects: 89
Study: 39486645

Group type: EXPERIMENTAL
Intervention: MDT (definitive local treatment to all sites of disease, plus SOC systemic therapy)
Number of subjects: 43

Group type: COMPARATOR
Intervention: SOC systemic therapy-only
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: MDT
Number of subjects: 43
Study: 39486684

Group type: EXPERIMENTAL
Intervention: BHIP prenatal diet-and-exercise intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual pregnancy care (UPC)
Number of subjects: 0
Study: 39486803

Group type: EXPERIMENTAL
Intervention: Dacryoendoscopic-assisted laser dacryoplasty with silicone intubation (DLDI)
Number of subjects: 522
Study: 39486811

Group type: EXPERIMENTAL
Intervention: Survey-based needs assessment
Number of subjects: 120

Group type: COMPARATOR
Intervention: Meeting-based needs assessment
Number of subjects: 120
Study: 39486818

Group type: EXPERIMENTAL
Intervention: Total B-IPQ score
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: Emotional representations (emotion and illness concern combined)
Number of subjects: 944

Group type: EXPERIMENTAL
Intervention: B-IPQ items for consequence, illness concern and emotion
Number of subjects: 944
Study: 39486820

Group type: EXPERIMENTAL
Intervention: Usual health communication plus an evidence summary ('fact box')
Number of subjects: 800

Group type: COMPARATOR
Intervention: Usual health communication
Number of subjects: 800
Study: 39486824

Group type: EXPERIMENTAL
Intervention: Prophylactic compression garments (compression class 2 (CCL2): 23-32 mm Hg) plus usual care
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 400
Study: 39486833

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy with bile cultures
Number of subjects: 703
Study: 39486886

Group type: EXPERIMENTAL
Intervention: Selective HDAC inhibition in combination with immunotherapy (specifics on dosage and duration not available)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pembrolizumab (NCT03419481)
Number of subjects: 0
Study: 39486892

Group type: EXPERIMENTAL
Intervention: Automated oxygen administration (AOA) via the O2matic device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Standard care (manual oxygen administration)
Number of subjects: 60
Study: 39486904

Group type: EXPERIMENTAL
Intervention: HPV-based cervical screening
Number of subjects: 395725

Group type: COMPARATOR
Intervention: Cytology-based screening
Number of subjects: 395725

Group type: EXPERIMENTAL
Intervention: HPV-negative at baseline
Number of subjects: 395725

Group type: COMPARATOR
Intervention: Normal cytology
Number of subjects: 395725

Group type: EXPERIMENTAL
Intervention: HPV-positive with negative cytology triage
Number of subjects: 395725

Group type: EXPERIMENTAL
Intervention: HPV 16 or HPV 18-positive with negative cytology triage
Number of subjects: 395725
Study: 39487320

Group type: EXPERIMENTAL
Intervention: TNFmAb
Number of subjects: 57

Group type: COMPARATOR
Intervention: No TNFmAb
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 57
Study: 39487326

Group type: EXPERIMENTAL
Intervention: Adapalene 0.1%-clindamycin 1% combination gel
Number of subjects: 1617

Group type: COMPARATOR
Intervention: Adapalene 0.1% monotherapy
Number of subjects: 1617

Group type: COMPARATOR
Intervention: Clindamycin 1% monotherapy
Number of subjects: 1617
Study: 39487337

Group type: EXPERIMENTAL
Intervention: 200 mg cilostazol daily for 7 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: 20 mg rosuvastatin daily for 7 days
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination of 200 mg cilostazol and 20 mg rosuvastatin daily for 7 days
Number of subjects: 57
Study: 39487373

Group type: EXPERIMENTAL
Intervention: Adavosertib (200 mg qd or 175 mg bid) plus Olaparib (200 mg bid)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Adavosertib plus Olaparib
Number of subjects: 130
Study: 39487386

Group type: EXPERIMENTAL
Intervention: Culturally tailored patient navigation program (PN-LCNS) for 3 months with phone-based, bilingual support and additional resources.
Number of subjects: 288

Group type: COMPARATOR
Intervention: Standard patient navigation (control group).
Number of subjects: 288
Study: 39487418

Group type: EXPERIMENTAL
Intervention: Vanish (light curable resin-modified glass ionomer varnish)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Control (fluoride varnish)
Number of subjects: 53
Study: 39487428

Group type: EXPERIMENTAL
Intervention: Guided Self-Determination counselling
Number of subjects: 81

Group type: COMPARATOR
Intervention: Diet leaflet only (Control)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Overall participation in trial
Number of subjects: 81
Study: 39487522

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention (5 sessions of 100 minutes each)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Psychoeducational intervention
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 34
Study: 39487711

Group type: EXPERIMENTAL
Intervention: Nab-sirolimus (ABI-009) administered IV on days 1 and 8 of cycle 1, in combination with temozolomide (125 mg/m2) and irinotecan.
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Nab-sirolimus (ABI-009) at maximum tolerated dose (MTD) of 15 mg/m2.
Number of subjects: 33
Study: 39487813

Group type: EXPERIMENTAL
Intervention: Geriatric assessment-driven referral to rehabilitation services
Number of subjects: 265

Group type: COMPARATOR
Intervention: No referral to rehabilitation services (control)
Number of subjects: 265
Study: 39487818

Group type: EXPERIMENTAL
Intervention: ReSPECT plans
Number of subjects: 842

Group type: COMPARATOR
Intervention: Standalone 'do not attempt cardiopulmonary resuscitation' forms
Number of subjects: 842
Study: 39487824

Group type: EXPERIMENTAL
Intervention: Frailty incidence
Number of subjects: 2100000

Group type: EXPERIMENTAL
Intervention: Frailty prevalence
Number of subjects: 2100000

Group type: EXPERIMENTAL
Intervention: Transition to higher frailty state
Number of subjects: 2100000

Group type: EXPERIMENTAL
Intervention: Healthcare use and costs
Number of subjects: 2100000

Group type: EXPERIMENTAL
Intervention: Simulation projections
Number of subjects: 2100000

Group type: EXPERIMENTAL
Intervention: Scenario analysis
Number of subjects: 2100000
Study: 39487920

Group type: EXPERIMENTAL
Intervention: Radiomics analysis (performed on 60 patients with discrete tumors)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Morphomics analysis (performed on all 101 patients)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Combined radiomics and morphomics features
Number of subjects: 101
Study: 39488138

Group type: EXPERIMENTAL
Intervention: Vaginal laser treatment (3-6 applications)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Pelvic floor exercises (9-18 sessions)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both treatments (Vaginal laser and PFE)
Number of subjects: 46
Study: 39488216

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg orally twice per day after a 5-day titration period
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 123
Study: 39488224

Group type: EXPERIMENTAL
Intervention: QFR-guided strategy
Number of subjects: 2000

Group type: COMPARATOR
Intervention: FFR-guided strategy
Number of subjects: 2000

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2000
Study: 39488229

Group type: EXPERIMENTAL
Intervention: Integrated care model (group Problem Management Plus and antidepressant therapy)
Number of subjects: 487
Study: 39488230

Group type: EXPERIMENTAL
Intervention: Comprehensive geriatric assessment (CGA)
Number of subjects: 217

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 217

Group type: EXPERIMENTAL
Intervention: CGA
Number of subjects: 217
Study: 39488255

Group type: EXPERIMENTAL
Intervention: Chronic hypercapnia in COPD patients
Number of subjects: 1526

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1526
Study: 39488333

Group type: EXPERIMENTAL
Intervention: ORIENT diet
Number of subjects: 568
Study: 39488412

Group type: EXPERIMENTAL
Intervention: MammoWave AI-based classification algorithm
Number of subjects: 10000

Group type: COMPARATOR
Intervention: Conventional breast examination path (control)
Number of subjects: 10000
Study: 39488424

Group type: EXPERIMENTAL
Intervention: Standardised tACS (10 Hz)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Sham tACS
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: Personalised tACS
Number of subjects: 159
Study: 39488423

Group type: EXPERIMENTAL
Intervention: Total Built Environment (BE)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Accessibility to transit station
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Structural barriers in the BE
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Self-efficacy (ASES-8)
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: Fear of movement (BFOM)
Number of subjects: 212
Study: 39488430

Group type: EXPERIMENTAL
Intervention: ERS+SMS
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: ERS only
Number of subjects: 448

Group type: COMPARATOR
Intervention: SMS/control
Number of subjects: 448
Study: 39488485

Group type: EXPERIMENTAL
Intervention: Frontline regimens including cyclophosphamide, thalidomide and dexamethasone; bortezomib, cyclophosphamide and dexamethasone; thalidomide and dexamethasone.
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Transplantation-ineligible patients (N = 491).
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Transplantation-eligible patients (N = 452).
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Patients with known prognostic factors.
Number of subjects: 943
Study: 39488504

Group type: EXPERIMENTAL
Intervention: xanomeline/trospium chloride
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 39488538

Group type: EXPERIMENTAL
Intervention: Blood test based on mid-infrared (MIR) metabolic fingerprinting
Number of subjects: 382
Study: 39488549

Group type: EXPERIMENTAL
Intervention: Chemotherapy for genomic high-risk tumors
Number of subjects: 715

Group type: COMPARATOR
Intervention: No chemotherapy for genomic high-risk tumors
Number of subjects: 715

Group type: EXPERIMENTAL
Intervention: Endocrine therapy for genomic low-risk tumors
Number of subjects: 715

Group type: COMPARATOR
Intervention: No endocrine therapy for genomic low-risk tumors
Number of subjects: 715
Study: 39488557

Group type: EXPERIMENTAL
Intervention: 18-month meditation training
Number of subjects: 90

Group type: COMPARATOR
Intervention: Non-native language (English) training
Number of subjects: 90
Study: 39488677

Group type: EXPERIMENTAL
Intervention: REMS (medium security)
Number of subjects: 604

Group type: EXPERIMENTAL
Intervention: Low secure places
Number of subjects: 604
Study: 39488682

Group type: EXPERIMENTAL
Intervention: Baseline insulin
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Baseline C-peptide
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Baseline IRS (Insulin×0.0295 + C-peptide×0.00372)
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Baseline HbA1c
Number of subjects: 218

Group type: EXPERIMENTAL
Intervention: Baseline IRS
Number of subjects: 218
Study: 39488777

Group type: EXPERIMENTAL
Intervention: Active H-coil rTMS
Number of subjects: 17

Group type: COMPARATOR
Intervention: Sham H-coil rTMS
Number of subjects: 17
Study: 39488821

Group type: EXPERIMENTAL
Intervention: IcoSema (175 U icodec, 0.5 mg semaglutide)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Icodec (175 U)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Semaglutide (0.5 mg)
Number of subjects: 31
Study: 39488825

Group type: EXPERIMENTAL
Intervention: Berberine; specific dosage and duration not mentioned
Number of subjects: 0
Study: 39488941

Group type: EXPERIMENTAL
Intervention: Discomfort intolerance
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Discomfort avoidance
Number of subjects: 163
Study: 39489149

Group type: EXPERIMENTAL
Intervention: Clinic + digital intervention group
Number of subjects: 900

Group type: COMPARATOR
Intervention: Clinic-only group
Number of subjects: 900
Study: 39489284

Group type: EXPERIMENTAL
Intervention: Obese group
Number of subjects: 194

Group type: COMPARATOR
Intervention: Nonobese group
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Average daily step count
Number of subjects: 194
Study: 39489399

Group type: EXPERIMENTAL
Intervention: Community-based intervention consisting of five sessions plus four brief check-ins delivered by a Yup'ik Community Health Worker, with modifications to the local store environment to provide sugar-free water enhancers.
Number of subjects: 192

Group type: COMPARATOR
Intervention: Delayed treatment control arm with no intervention during the main study period.
Number of subjects: 192
Study: 39489541

Group type: EXPERIMENTAL
Intervention: OncoPrism-HNSCC assay in monotherapy cohort (n=62)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: OncoPrism-HNSCC assay in chemo-immunotherapy cohort (n=50)
Number of subjects: 112
Study: 39489653

Group type: EXPERIMENTAL
Intervention: Critical-Care Pain Observation Tool (CPOT)
Number of subjects: 725

Group type: COMPARATOR
Intervention: Control (pre-implementation of CPOT)
Number of subjects: 725
Study: 39489747

Group type: EXPERIMENTAL
Intervention: SY-5007
Number of subjects: 122
Study: 39489895

Group type: EXPERIMENTAL
Intervention: Nintedanib 150 mg orally twice per day (possible reduction to 100 mg twice per day in case of side-effects or hepatotoxicity) for 12 months.
Number of subjects: 30
Study: 39489924

Group type: EXPERIMENTAL
Intervention: Intensified alkylating chemotherapy (IACT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy (CDCT)
Number of subjects: 75
Study: 39489935

Group type: EXPERIMENTAL
Intervention: Phenotype 2 (28%) with nociplastic pain characteristics
Number of subjects: 217

Group type: COMPARATOR
Intervention: Phenotype 1 (72%)
Number of subjects: 217
Study: 39490766

Group type: EXPERIMENTAL
Intervention: QuitBot
Number of subjects: 760

Group type: COMPARATOR
Intervention: Smokefree TXT (SFT)
Number of subjects: 760